PaxVax nails down $62M to complete vaccine buyout, PhIII study

Redwood City, CA-based PaxVax has nailed down up to $50 million in debt financing and $12 million in a Series B venture funding extension to complete the acquisition of Crucell's oral typhoid vaccine Vivotif and the ongoing Phase III study of its cholera vaccine candidate, PXVX0200. In addition to NIH grants, PaxVax has raised $80 million from equity investors including Ignition Ventures, Ignition Growth Capital and the Blue Haven Initiative. "With its recent acquisition of Vivotif from Crucell, PaxVax has emerged as an exciting new player in the global travel vaccine market," said Martin Friedman, managing member of Pharmakon Advisors, which is providing the debt financing. Release

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.